A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with RAS/RAF Wild-Type Recurrent Metastatic Colorectal Cancer Who Have Received or Intolerant to Prior Chemotherapy

Disease Sites:

Colon, Rectal

Staging:

Phase III

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics

Drugs:

Amivantamab, Bevacizumab, Cetuximab, FOLFIRI (Leucovorin, 5-FU, Irinotecan)

Principal Investigator(s):

Eng, Cathy

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

09-19-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTGIT24167

National Clinical Trial ID:

NCT06750094

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available